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Zusammenfassung
!
Hintergrund: Angesichts des Potenzials der Ko-
loskopie hinsichtlich Prävention und Früherken-
nung von Darmkrebs ist deren bevölkerungsweite
Inanspruchnahme ein wichtiger Parameter, um
die zukünftige Krankheitslast abzuschätzen. Ziel
der Studie war es, die insgesamte Prävalenz und
die Determinanten koloskopischer Untersuchun-
gen in Deutschland zu untersuchen, einem Land
mit langjähriger Darmkrebsvorsorge.
Methodik: Die Daten wurden im Jahr 2004 im
Rahmen des Health Care Access Panels, einer bun-
desweit repräsentativen Befragung deutscher
Haushalte, erhoben. Die Stichprobe umfasste
15810 Männer und Frauen im Alter zwischen 50
und 70 Jahren, ohne Krebsvorgeschichte.
Ergebnisse: Insgesamt gaben 36% der Befragten
an, dass sie in der Vergangenheit mindestens ein-
mal koloskopisch untersucht wurden (25% ein-
malig und 11% mehr als einmal). Die Prävalenz
koloskopischer Untersuchungen stieg mit dem
Alter steil an (von 25% in der Altergruppe 50–54
bis zu 43% in der Altersgruppe 65–70) und unter-
schied sich kaum zwischen Frauen und Männern.
Die frühere Durchführung eines Tests auf Blut im
Stuhl war bei beiden Geschlechtern das wich-
tigste Korrelat einer koloskopischen Untersu-
chung.
Schlussfolgerung: Nach unserem Survey aus
dem Jahr 2004 wurde bei mehr als einem Drittel
der deutschen Bevölkerung bis zum 70. Lebens-
jahr mindestens einmal eine Koloskopie durchge-
führt. Zum Zeitpunkt der Befragung war der Test
auf Blut noch das gebräuchlichste Verfahren in
der Darmkrebsvorsorge. Längerfristig ist davon
auszugehen, dass die Früherkennungs-Koloskopie
zu Veränderungen in der Inanspruchnahme der
Koloskopie führen wird. Die Ergebnisse dieses
Surveys können als Bezugspunkt dienen, um ent-
sprechende Veränderungen zu charakterisieren
und zu quantifizieren.
Abstract
!
Background: Given the potential colonoscopy
has in prevention and early detection of colorectal
cancer (CRC), its overall use within a population is
a meaningful parameter to estimate the future
CRC burden. We aimed to examine overall preva-
lence and correlates of colonoscopy use in Germa-
ny, a country with a long-standing, opportunistic
CRC screening programme.
Methods: The data were collected in 2004
through the Health Care Access Panel, a nationally
generalisable survey of German households. The
sample comprised 15,810 men and women aged
50 to 70 years without a personal history of can-
cer.
Results: Overall, 36% of respondents reported to
have had at least one colonoscopy in the past
(25% once and 11% more than once). Prevalence
of colonoscopy use strongly increased by age
(from 25% to 43% in age groups 50–54 and 65–
70, respectively), but hardly differed by sex. Pre-
vious faecal occult blood testing (FOBT) was the
most important correlate of colonoscopy use in
either sex.
Conclusions: Our survey from 2004, when FOBT
was still the most important screening tool in
Germany, suggests that more than one third of
the German population underwent colonoscopy
at least once up to age 70. While introduction of
screening colonoscopy is expected to impact on
overall colonoscopy use in the long run, these
data can serve as point of reference to assess the
extent and the patterns of such changes.
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Introduction
!
Colorectal cancer (CRC) is among the most common cancers
worldwide, with incidence rates being particularly high in in-
dustrialised countries [1]. The preventive potential colonos-
copies, by allowing the removal of precursor lesions, has been
increasingly recognised. Recent observational studies have
shown a strong inverse association between the risk of devel-
oping CRC and (ever) use of colonoscopy (irrespective of indi-
cation) [2–5]. Thus, the overall colonoscopy use of a popula-
tion may become a meaningful parameter to estimate future
CRC burden. Apart from this public health relevance, overall
colonoscopy use is an important parameter in terms of esti-
mating colonoscopy-related health care costs and required ca-
pacities.
Overall colonoscopy use in the general population is difficult
to estimate because there are different reasons that could
lead to colonoscopy, such as gastrointestinal symptoms or
CRC screening (e.g., a follow-up colonoscopy after a positive
FOBT). Furthermore, it is expected that there is a certain over-
lap between colonoscopies (formally) performed in the context
of CRC screening and colonoscopies performed due to symp-
toms. Population-based health surveys are therefore an impor-
tant tool to estimate the overall colonoscopy use in the gener-
al population. While such survey data are abundantly available
for the U.S. population collected within national health sur-
veys on a regular basis (Behavioral Risk Factor Surveillance
System, National Health Interview Survey), corresponding esti-
mates are extremely scarce for European countries [6].
In Germany, a population-based CRC screening programme
with annual FOBT and colonoscopic follow-up of positive test
results has been offered since 1977 to individuals from age
50. While FOBT screening continues to be offered, screening
colonoscopy was introduced in late 2002 as an alternative to
FOBT screening from age 55. Participation rates in screening
colonoscopy, which are documented in detail (stratified by
age, sex and year) within a national screening colonoscopy da-
tabase are low [7]. Generally, there is no organised structure
of inviting or reminding individuals to participate in colorectal
cancer screening, i. e., it is an opportunistic screening pro-
gramme. All screening-related costs are covered by the man-
datory health insurance.
The aim of this study was to assess the overall colonoscopy
use in Germany in 2004, a country where an opportunistic
CRC screening programme has been in place for more than
30 years, by means of a large, nationally representative survey.
Participants and Methods
!
Study population and setting
The data for this study were collected within the Health Care
Access Panel (HCAP) of the year 2004. The HCAP, which was
first carried out in 1999, is a large German household panel
survey which was developed as a multi-purpose database pro-
viding information about chronic diseases and health-care uti-
lisation in the general population. It uses a sampling method
specifically designed to arrive at representative population
samples. Furthermore, individual weighting factors are calcula-
ted to account for slight deviations from the general popula-
tion with respect to age, sex and region. The validity of data
provided by the HCAP in terms of its representativeness has
been carefully checked and confirmed by comparison with na-
tional data sources provided by the German Federal Office for
Statistics and previous health surveys [8, 9]. The HCAP of the
year 2004 contained 71,446 persons aged 20–70 years and
the household response rate was 58%. For the present study
only respondents ≥50 years were included (n =17,146). 1,336
persons with a personal history of cancer were excluded from
the study. The final sample for the present study comprised
15,810 adults aged 50–70 years.
Data collection
Data collection took place between August and October 2004
by mailed questionnaires. Due to delayed data processing and
prioritising of other research questions, we analysed the data
regarding colonoscopy use only in 2009. The development of
the questionnaire included piloting and pre-testing of the
items in independent samples to ensure its clarity and com-
prehension.
Participants were asked if they had undergone colonoscopy in
the past (assessed by the German colloquial term ‘Darmspiege-
lung’ for colonoscopy) with the possible answers “never”,
“once” and “more than once”. In addition, we assessed poten-
tial correlates of colonoscopy use: Information on past adher-
ence to FOBT screening (possible answers “never”, “irregular-
ly”, “regularly every 1–2 years”), and sociodemographic data
including age in years, marital status, family size, education
(9th grade or under, 10th grade, high school certificate, college
graduate), monthly family income and health insurance status
(public versus private) were collected. Family history of cancer
was assessed by asking the participants whether they had
knowledge of (any) cancer amongst their grandparents, par-
ents or siblings (“no”; “yes, one person”; “yes, two or more
persons”). Physician’s recommendation was assessed by asking
participants whether a physician had recommended that they
undergo a test for the early detection of cancer (1 = yes, 0 =no/
I don’t know). General medical check-up was measured by
asking participants to indicate on a four-point scale (“never”,
“irregularly”, “every two years” or “annually”) whether and
how regularly they had attended a free medical check-up as
provided by the German health-care system starting at age 35.
Statistical analysis
The study population was described with respect to age, socio-
demographic variables, physician’s recommendation for cancer
screening and utilisation of preventive health-care; sex differ-
ences were assessed using chi square statistics. Colonoscopy
use was first assessed on a three-point scale according to the
original answers (“never”, “once”, “more than once”). In the
following analyses the three-point variable was dichotomised
into “ever colonoscopy use” (i. e., at least one colonoscopy)
and “never colonoscopy use”. The prevalence of “ever colono-
scopy use” was stratified by age and sex. We further estimated
the prevalence of “ever colonoscopy use” stratified by age and
sex for the scenario that screening colonoscopy would not
have been offered. The latter estimate was derived from the
annual adherence to screening colonoscopy since its introduc-
tion, i. e., two years before this survey was conducted (ranging
from 2–5%, see Supplementary Table in Appednix) and taking
into account that a certain proportion of people participating
in screening colonoscopy had another colonoscopy before (see
Appendix for the formulae and parameters used to compute
these estimates).
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chotomised variable “ever colonoscopy use” as described above)
we performed multivariable logistic hierarchical regression ana-
lyses taking into account potential clustering within the data. The
analyses were done stratified by sex analogously to previous ana-
lyses of the survey data regarding correlates of FOBTuse [10]. So-
ciodemographic variables were entered in the first step and all
other variables (family history of cancer, use of medical check-
ups, physician recommendation, FOBT use) in the second step.
We used adjusted odds ratios (ORs) and 95% confidence intervals
(CI) to summarise the results of the logistic regressions.
Except for the description of the study population (●▶ Table 1),
we weighted the variables in all analyses according to the in-
dividual weights to optimise representativeness of the results.
Statistical analyses were carried out using SPSS for Windows
(Version 14).
Results
!
The overall sample of 15,810 participants comprised 7,735
men (48.9%) and 8,075 women (51.1%). The mean age was
58 years (men: 58.3, SD=5.5; women 58.1, SD=5.7). Further
characteristics of the study population are shown in●▶ Table 1.
The distributions of sociodemographic variables mirror the so-
cioeconomic differences between men and women in the gen-
eral German population (Federal Statistical Office, 2005). Wo-
men reported more often a family history of cancer than
men. They also reported more frequently to have received a
physician’s recommendation for cancer screening and to have
utilised preventive health-care measures including FOBT
screening.
Table 1 Characteristics of the
study population.
men (n=7735) women (n=8075) p value
variable1 n (%) n (%)
age (years) < 0.01
50 – 54 2439 (31.5) 2761 (34.2)
55– 59 2066 (26.7) 2027 (25.1)
60 – 64 1938 (25.1) 1950 (24.1)
65– 70 1292 (16.7) 1337 (16.6)
marital status < 0.001
married 6414 (83.0) 5589 (69.2)
single/separated/divorced/widowed 1316 (17.0) 2484 (30.8)
family size < 0.001
1 867 (11.2) 16860 (20.9)
2 3997 (51.7) 4341 (53.8)
3 1563 (20.2) 1341 (16.6)
4 950 (12.3) 531 (6.6)
≥ 5 358 (4.6) 176 (2.2)
education < 0.001
9th grade or under 3655 (48.7) 3926 (49.6)
10th grade 1825 (24.3) 2635 (33.3)
High school graduation 591 (7.9) 499 (6.3)
College graduation 1435 (19.1) 849 (10.7)
family income per month < 0.001
< 1,750 € 2409 (33.1) 3425 (45.1)
1750 € – 2749 € 2578 (35.4) 2387 (31.4)
≥ 2750 € 2296 (31.5) 1781 (23.5)
health insurance < 0.001
public 6563 (86.0) 7418 (92.5)
private 1068 (14.0) 601 (7.5)
family cancer history < 0.001
no 4646 (60.9) 4170 (52.1)
yes: 1 person 2282 (29.9) 2605 (32.6)
yes: ≥ 2 persons 705 (9.2) 1225 (15.3)
physician’s recommendation (cancer screening) < 0.001
no 3519 (46.4) 2683 (33.9)
yes 4064 (53.6) 5230 (66.1)
medical check-up < 0.001
never 1957 (25.6) 1133 (14.2)
irregularly 2160 (28.2) 1918 (24.0)
every two years 1609 (21.0) 1779 (22.3)
every year 1927 (25.2) 3154 (39.5)
FOBT < 0.0001
never 2323 (31.2) 1393 (17.9)
irregularly 1854 (24.9) 1530 (19.6)
regularly every 1– 2 years 3281 (44.0) 4869 (62.5)
1 N for each variable varies slightly due to missing data, which varied from 0 – 5.9 %.
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bSonderdruckfürprivateZweckedesAutors Prevalence of colonoscopy useOverall, the proportion of participants without previous colo-noscopy was 64.4%, while 24.6% had one colonoscopy and11.0% had more than one colonoscopy in the past. The propor-tion of respondents with “never colonoscopy” was slightlyhigher in men than in women (66 vs. 63%), but this sex differ-ence was marginal in size, although statistically significant(p <0.01, Cramer’s V =0.04). Accordingly, the proportion of re-spondents reporting “one colonoscopy” was slightly higher inwomen than in men (26 vs. 23%), while the proportion report-ing “more than one colonoscopy” was the same in both sexes(11%). Prevalence of previous colonoscopy use increased withage (●▶ Fig. 1). The proportion of participants with one pre-
vious colonoscopy increased from 17% in age group 50–54 to
29% in age group 65–70. The increase with age was less pro-
nounced regarding prevalence of “more than one colonosco-
py”, which was 8% in age group 50–54 and increased to 14%
in age group 65–70.
●▶ Fig. 2 shows lifetime prevalence of colonoscopy use (i. e., one
colonoscopy or more) stratified by age and sex. In age group
50–54 one quarter of both men and women had at least one
previous colonoscopy. Lifetime prevalence strongly increased
with age and was slightly higher in women than men in all
age groups. The highest prevalence of colonoscopy use was ob-
served in women aged 65–70, amounting to 45%. When esti-
mating life-time prevalence of overall colonoscopy use for the
scenario that screening colonoscopy would not have been of-
fered, the proportions decreased by about 6–8% in the differ-
ent strata above age 55. Again the prevalence of colonoscopy
use was estimated to be highest in age group 65–70, amount-
ing to 39% in women and 35% in men (see Appendix).
Correlates of colonoscopy use stratified by sex
As described in the methods section, sociodemographic vari-
ables were entered first and followed by the remaining vari-
ables in a second step. The explained variance in the models ad-
justing for sociodemographic variables (including age) was very
small (Nagelkerke’s R2 =0.01 for either sex) (data not shown).
●▶ Table 2 shows the ORs for the correlates of lifetime colono-
scopy use adjusted for all variables and stratified by sex. Several
variables showed sex-specific patterns regarding their associa-
tion with colonoscopy use. Age correlated with previous colono-
scopy use in both sexes, but the association was more distinct
among women. Family size was inversely associated with colo-
noscopy use in men but not in women. Income was not associ-
ated with colonoscopy use in men, while among women the
odds of having had a colonoscopy were statistically higher in
the highest compared to the lowest income group. As to educa-
tion, there was no clear association or trend in both sexes and
also the type of health insurance (private versus public) did not
correlate with colonoscopy use. Family history of cancer was
significantly associated with colonoscopy use both among men
and women, but was more pronounced in women. Among
men, only those reporting two or more relatives with cancer
showed increased ORs. Regular medical check-ups correlated
with colonoscopy use in both men and women, but the associa-
tion was again more pronounced in women. By contrast, physi-
cian’s recommendation to undergo cancer screening tests was
associated with colonoscopy use only in men. Previous FOBT
use showed the strongest association with colonoscopy use in
both men and women. Adding use of medical check-ups, physi-
cian’s recommendation, family history of cancer and previous
FOBT use led to a marked increase in explained model variance
(Δ Nagelkerke’s R2men =0.24, Δ Nagelkerke’s R2women =0.17). The
increase was higher for men than for women suggesting that
these variables are better combined predictors regarding colo-
noscopy use in men.
Discussion
!
This large health survey from 2004 showed that a substantial
proportion of the German population between age 50 and 70
had at least one previous colonoscopy. Self-reported lifetime
prevalence of colonoscopy use was already 25% in age group
50–55, rising to 40% and more in higher age groups. Adher-
ence to previous FOBT screening, introduced in 1977, was the
most important predictor of lifetime colonoscopy use, both in
men and in women. About 6–8% of lifetime colonoscopy use
in 2004 was estimated to be attributable to the screening co-
lonoscopy programme which has been introduced in late 2002
and shows comparatively low annual adherence rates. Accord-
ing to a representative cross-sectional survey from 2008, about
42% of the German population aged 55–69 reported to have
ever had a colonoscopy, compared to 40% in the same age
group in our survey from 2004. Even though the survey from
2008 included only 423 subjects in age group 55–69, the data
do not indicate a substantial increase in overall colonoscopy
use since 2004, despite the continuous offer of screening colo-
noscopy [11].
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Data allowing the comparison of colonoscopy use between Ger-
many and other European countries are very scarce. In France,
where population-wide FOBT screening was stepwise intro-
duced during the last few years only, a large survey conducted
in 2006 reported a lifetime prevalence of colonoscopy use of
18% (Institute for Research and Information in Health Econom-
ics, 2006) [12]. Even though interpretation of the latter is limited
due to lack of information regarding the underlying age distri-
bution, a lower lifetime prevalence of colonoscopy use in France
compared to Germany would be highly plausible given the time
gap in terms of introducing FOBT screening. In Austria, where
population-wide CRC screening based on FOBT or lower endo-
scopy is recommended but cost coverage varies by region, about
25% of the population between 40–79 years have undergone a
colonoscopy according to a survey from 2005 [13]. Another Eu-
ropean data source originating from Greece, where population-
Table 2 Results frommultivariate
logistic hierarchical regression
(2nd step) predicting colonoscopy
use1 among men and women aged
55 to 70 years2.
men (n=5258) women (n=5263)
OR3 (95% CI) OR3 (95% CI)
sociodemographic variables
age
55 – 59 1.00 1.00
60 – 64 1.28** (1.09 – 1.51) 1.31*** (1.13 – 1.51)
65 – 70 1.20* (1.01 – 1.43) 1.55*** (1.33 – 1.80)
marital status
No 1.00 1.00
Yes 1.20 (0.90 – 1.59) 0.93 (0.75 – 1.16)
family size
1 1.00 1.00
2 0.57** (0.42 – 0.79) 0.94 (0.74 – 1.20)
3 0.60** (0.42 – 0.87) 0.95 (0.70 – 1.29)
4 0.65 (0.41 – 1.02) 0.81 (0.49 – 1.33)
more than 4 0.49* (0.27 – 0.89) 1.67 (0.75 – 3.08)
family income per month
< 1 750 € 1.00 1.00
1 750 – 2 749 € 0.98 (0.83 – 1.15) 1.07 (0.93 – 1.24)
≥ 2 750 € 0.85 (0.71 – 1.03) 1.36** (1.13 – 1.64)
education
9th grade or under 1.00 1.00
10th grade 1.09 (0.91 – 1.29) 0.98 (0.86 – 1.12)
High school degree 1.35* (1.05 – 1.74) 0.83 (0.64 – 1.06)
College degree 1.16 (0.96 – 1.39) 0.88 (0.70 – 1.08)
health insurance
public 1.00 1.00
private 1.04 (0.85 – 1.27) 0.94 (0.75 – 1.20)
other variables
family history of cancer
no 1.00 1.00
one family member 1.06 (0.91 – 1.22) 1.30*** (1.14 – 1.47)
two or more family members 1.38** (1.11 – 1.73) 1.60*** (1.31 – 1.85)
medical check-up
never 1.00 1.00
irregularly 1.00 (0.78 – 1.28) 1.13 (0.90 – 1.44)
every two years 1.16 (0.90 – 1.50) 1.63** (1.29 – 2.05)
annually 1.57*** (1.22 – 2.02) 1.88*** (1.50 – 2.34)
physician’s recommendation (cancer screening)
no 1.00 1.00
yes 1.26** (1.09 – 1.45) 1.08 (0.95 – 1.23)
FOBT
never 1.00 1.00
irregularly 8.40*** (6.38 – 11.05) 8.43*** (6.30 –11.26)
regularly every
1 – 2 years
11.22*** (8.49 – 14.81) 10.41*** (7.89 – 13.74)
1 Coding: 0 = no, 1 = yes.
2 As screening colonoscopy is only offered to people from age 55 we excluded participants below age 55 when examining
correlates of life-time colonoscopy use to ensure homogeneity and comparability in this regard.
3 Odds ratios (OR) are adjusted for all other variables entered: age, marital status, family size, family income, education,
health insurance, family history of cancer, medical checkup, physician’s recommendation and FOBT use; text in italics
indicates statistically significant associations for test of difference from respective reference category; significance of
Wald-statistic: * p < 0.05, ** p < 0.01, *** p < 0.001; Nagelkerke’s R2 (men) = 0.25, Nagelkerke’s R2 (women) = 0.19, all
from final step; Hosmer-Lemeshow Goodness of Fit test (men): χ2 = 10.54, df = 8, p = 0.23; Hosmer-Lemeshow Goodness
of Fit test (women): χ2 = 11.90, df = 8, p = 0.16.
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wide CRC screening has not been implemented, reported esti-
mates on recent use of lower endoscopy (colonoscopy or sig-
moidoscopy) of about 7–9% [14].
The comparison of data from the USA with the data from this
German survey is encumbered for the following reason: while
sigmoidoscopy is rarely done in Germany and not offered as a
screening tool [4], it has been used for primary screening in
the US for several years (as an alternative to FOBT screening).
It has been shown that sigmoidoscopy cannot reliably be dis-
tinguished from colonoscopy by self-report [15]. U.S. health
surveys therefore typically report the use of lower gastroin-
testinal endoscopy as a combined estimate for sigmoidoscopy
and colonoscopy use. The National Health Interview Survey
from 2000 reported lifetime prevalence of lower endoscopy
use being 39% for respondents aged ≥50 years [16], and 43%
for respondents aged ≥65 years [17]. The latter estimate rose
to 48% in 2003, i. e., two years after screening colonoscopy
was covered by Medicare [17].
The above-mentioned data sources are generally not indicative
of pronounced sex differences in prevalence of endoscopy use.
However, slightly higher prevalences in men than in women
are reported for some countries [6, 18–20], while in Germany
it seems to be vice versa. The higher proportion of women
with previous colonoscopy in Germany may be attributed to
the significant sex differences in adherence to FOBT screening,
as reported previously [10]. However, the fact that the ob-
served sex differences in colonoscopy use were small lends
support to previous findings of a higher FOBT positivity rate
in men compared with women leading to a higher number of
follow-up colonoscopies in men than in women [21, 22]. Given
that in Germany women tend to show higher adherence to
screening colonoscopy than men, the sex difference regarding
overall colonoscopy use could further increase in the long run
[23].
As to other potential correlates, the marginal associations with
socioeconomic variables indicate no or only very little social
inequality in access to colonoscopy. This may reflect the
health-care system in Germany where everyone has health in-
surance, whereas, for example, in the USA these variables have
been shown to be important predictors of endoscopy use [24].
The reasons for sex-specific patterns of certain correlates
would require further investigation.
The present study used a cross-sectional design limiting inter-
pretation of the observed data in terms of age effects and
causality of associations. Interpretation of our data is further
limited by the fact that information on previous colonoscopy
was based on self-reports only. However, validation studies
from Germany and other countries verifying self-reported co-
lonoscopies by comparison with medical records found that
self-reported data on previous colonoscopy use are highly reli-
able [25–27]. We did not collect information on reasons for
colonoscopy. Even though such information would be of inter-
est, validity of self-reported data in terms of distinguishing be-
tween indications (diagnostic colonoscopy vs. screening colo-
noscopy) has been reported to be limited [25].
Specific strengths of our study pertain to the large sample,
which was drawn using a method to arrive at samples repre-
senting the general population. Furthermore, we collected de-
tailed information regarding potential correlates of colonosco-
py use, including adherence to FOBT screening stratified by
screening behaviour groups. We collected our data in 2004,
when the screening colonoscopy programme, introduced in
late 2002, had still a small impact on overall colonoscopy use.
Our data thus provide a valuable point of reference regarding
future developments, e.g., the long-term effect of screening co-
lonoscopy or changes in the screening programme. The Ger-
man CRC screening programme is currently opportunistic.
Higher colonoscopy use would be expected when switching
to an organised programme with invitations and reminders,
which is a point of ongoing discussion. Furthermore, FOBT
screening in Germany is currently based on the guaiac-based
FOBT showing high specificity (and low sensitivity). An even
higher prevalence of (diagnostic) colonoscopy use is to be ex-
pected if newer FOBTs with lower specificity (and higher sen-
sitivity) were used for screening, e.g., certain immunochemical
FOBTs [28], which would lead to a higher number of false-
positive test results being followed-up by colonoscopy.
In conclusion, our survey from 2004, when faecal occult blood
testing (offered since more than 30 years) was still the most
important CRC screening tool in Germany, suggests that more
than one third of the population underwent colonoscopy at
least once up to age 70. While introduction of screening colo-
noscopy or further potential modifications of the screening
programme (such as the introduction of an invitation system)
are expected to impact on overall colonoscopy use in the long
run, these data can serve as point of reference to assess the
extent and the patterns of such changes.
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Appendix
!
Lifetime prevalence of colonoscopy use in 2004 (stratified by
age and sex) for the scenario that screening colonoscopy,
which has been introduced in late 2002, would not have been
offered was estimated as follows.
First, the number of respondents in the respective age and sex
group who had a previous colonoscopy which was not related
to the screening colonoscopy programme was derived as fol-
lows and denoted n(everColadj)age,sex:
n(everColadj)age,sex = n(everCol)age,sex – nage,sex × C(ScreenCol)age,sex,
year1 × (1–PprevCol) – nage,sex × C (ScreenCol)age,sex,year2 × (1–Pprev-
Col)
where
▶ n(everCol)age,sex is the number of respondents in the respective
age and sex group who reported a previous colonoscpy in the
survey,
▶ nage,sex is the overall number of respondents in the respective
age and sex group,
▶ C(ScreenCol)age,sex,year1 and C(ScreenCol)age,sex,year2 are the an-
nual compliance rates with screening colonoscopy 2 years
after its introduction (i. e., 2 years before the survey was con-
ducted) in the respective age and sex group (●▶ Table Appen-
dix),
▶ PprevCol is the proportion of people who undergo screening
colonscopy and had another colonoscopy before (i. e., screen-
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Fig. Appendix Estimated lifetime prevalence of colonoscopy use in
2004for the scenario that screening colonoscopy would not have been
offered, stratified by age and sex.
Table Appendix Compliance
with screening colonoscopy strati-
fied by age and sex in the two years
after its introduction [7]; Percenta-
ges refer to the number of inhibi-
tants in the respective age and sex
group.
women men
year age group
55–59 60–64 65–70 55–59 60–64 65–70
2003 3.5% 4.1% 3.1% 2.2% 3.0% 2.7%
2004 4.4% 5.0% 3.8% 3.0% 4.0% 3.5%
Sieverding M et al. Colonoscopy Use in… Z Gastroenterol 2010; 48: 1351–1357
Originalarbeit 1357
